Compare Core Scientific Inc (CORZ) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Johnson & Johnson — how do they compare? Core Scientific Inc trades at $15.49 (market cap $4.94B), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 125.1× Core Scientific Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Johnson & Johnson for 129 Days on average.
| CORZ | JNJ | |
|---|---|---|
Market Cap | $4.94B | $618.09B |
Volume | 15,630,800 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $29.16 | $278.43 |
52-Week Low | $13.57 | $186.00 |
Typical Hold Time | 20 Days | 129 Days |
Enterprise Value | $7.46B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.41, down 3.32% today, with bearish technical signals and significant fundamental challenges. The company reported a net loss of $288.62 million in 2025 with negative profit margins, though revenue grew to $319.02 million. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.75 consensus price target, while recent news highlights the company's pivot toward AI data center operations and insider buying activity.
Despite strong analyst support, CORZ faces substantial execution risks in its AI infrastructure transition amid persistent losses and negative cash flow. The stock's current price near key support levels presents potential upside if the company can achieve profitability, but investors should weigh the high-risk profile against the optimistic Wall Street projections.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
